AMNEAL PHARMACEUTICALS, INC. Increase (Decrease) in Accounts Receivable
AMNEAL PHARMACEUTICALS, INC. (AMRX) reported Increase (Decrease) in Accounts Receivable of $125.77 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-06
- AMNEAL PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was $169.78M, a 215.79% increase year-over-year.
- AMNEAL PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was -$44.01M.
- AMNEAL PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was $10.34M, a 63.86% decline year-over-year.
- AMNEAL PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was $77.61M.
- AMNEAL PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for fiscal 2025 was $120.57M, a 25.87% decline from fiscal 2024.
- AMNEAL PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for fiscal 2024 was $162.64M.
- AMNEAL PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for fiscal 2023 was -$126.29M, a 258.42% decline from fiscal 2022.
- AMNEAL PHARMACEUTICALS, INC. increase (decrease) in accounts receivable for fiscal 2022 was $79.72M, a 237.48% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $169.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $125.77M 10-Q · filed 2026-08-06 | $136.10M derived: sum of 3 quarters · filed 2026-08-06 | $213.72M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$44.01M 10-Q · filed 2026-05-07 | -$33.67M derived: sum of 2 quarters · filed 2026-05-07 | $43.94M derived: sum of 3 quarters · filed 2026-05-07 | $97.70M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $10.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $87.95M derived: sum of 2 quarters · filed 2026-02-27 | $141.71M derived: sum of 3 quarters · filed 2026-08-06 | $120.57M 10-K · filed 2026-02-27 |
| 2025-09-30 | $77.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $131.38M derived: sum of 2 quarters · filed 2026-08-06 | $110.23M 10-Q · filed 2025-11-06 | $138.83M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $53.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $32.62M 10-Q · filed 2026-08-06 | $61.22M derived: sum of 3 quarters · filed 2026-08-06 | $39.41M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$21.15M 10-Q · filed 2026-05-07 | $7.46M derived: sum of 2 quarters · filed 2026-05-07 | -$14.35M derived: sum of 3 quarters · filed 2026-05-07 | $86.32M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $28.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $6.79M derived: sum of 2 quarters · filed 2026-02-27 | $107.46M derived: sum of 3 quarters · filed 2026-02-27 | $162.64M 10-K · filed 2026-02-27 |
| 2024-09-30 | -$21.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $78.86M derived: sum of 2 quarters · filed 2025-11-06 | $134.03M 10-Q · filed 2025-11-06 | $56.80M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | $100.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $155.84M 10-Q · filed 2025-08-07 | $78.61M derived: sum of 3 quarters · filed 2026-02-27 | $96.53M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | $55.17M 10-Q · filed 2025-05-07 | -$22.06M derived: sum of 2 quarters · filed 2026-02-27 | -$4.14M derived: sum of 3 quarters · filed 2026-02-27 | $124.85M derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | -$77.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$59.31M derived: sum of 2 quarters · filed 2026-02-27 | $69.68M derived: sum of 3 quarters · filed 2026-02-27 | -$126.29M 10-K · filed 2026-02-27 |
| 2023-09-30 | $17.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $146.91M derived: sum of 2 quarters · filed 2024-11-12 | -$49.05M 10-Q · filed 2024-11-12 | $64.23M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $128.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | -$66.98M 10-Q · filed 2024-08-09 | $46.31M derived: sum of 3 quarters · filed 2025-02-28 | -$13.82M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | -$195.97M 10-Q · filed 2024-05-08 | -$82.68M derived: sum of 2 quarters · filed 2025-02-28 | -$142.81M derived: sum of 3 quarters · filed 2025-02-28 | $8.02M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $113.29M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $53.16M derived: sum of 2 quarters · filed 2025-02-28 | $203.99M derived: sum of 3 quarters · filed 2025-02-28 | $79.72M 10-K · filed 2025-02-28 |
| 2022-09-30 | -$60.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $90.70M derived: sum of 2 quarters · filed 2023-11-09 | -$33.57M 10-Q · filed 2023-11-09 | $945.00K derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-06-30 | $150.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $26.56M 10-Q · filed 2023-08-08 | $61.08M derived: sum of 3 quarters · filed 2024-03-14 | $37.02M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-03-31 | -$124.27M 10-Q · filed 2023-05-09 | -$89.75M derived: sum of 2 quarters · filed 2024-03-14 | -$113.81M derived: sum of 3 quarters · filed 2024-03-14 | $7.74M derived: sum of 4 quarters · filed 2024-03-14 |
| 2021-12-31 | $34.52M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $10.45M derived: sum of 2 quarters · filed 2024-03-14 | $132.01M derived: sum of 3 quarters · filed 2024-03-14 | $23.62M 10-K · filed 2024-03-14 |
| 2021-09-30 | -$24.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $97.49M derived: sum of 2 quarters · filed 2022-11-07 | -$10.89M 10-Q · filed 2022-11-07 | -$78.43M derived: sum of 4 quarters · filed 2023-03-03 |
| 2021-06-30 | $121.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $13.17M 10-Q · filed 2022-08-08 | -$54.37M derived: sum of 3 quarters · filed 2023-03-03 | $72.15M derived: sum of 4 quarters · filed 2023-03-03 |
| 2021-03-31 | -$108.39M 10-Q · filed 2022-05-06 | -$175.92M derived: sum of 2 quarters · filed 2023-03-03 | -$49.40M derived: sum of 3 quarters · filed 2023-03-03 | -$186.06M derived: sum of 4 quarters · filed 2023-03-03 |
| 2020-12-31 | -$67.53M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03 | $58.98M derived: sum of 2 quarters · filed 2023-03-03 | -$77.68M derived: sum of 3 quarters · filed 2023-03-03 | -$16.79M 10-K · filed 2023-03-03 |
| 2020-09-30 | $126.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | -$10.14M derived: sum of 2 quarters · filed 2021-11-08 | $50.75M 10-Q · filed 2021-11-08 | $137.02M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | -$136.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | -$75.77M 10-Q · filed 2021-08-09 | $10.50M derived: sum of 3 quarters · filed 2022-03-01 | -$106.00M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $60.89M 10-Q · filed 2021-05-07 | $147.16M derived: sum of 2 quarters · filed 2022-03-01 | $30.66M derived: sum of 3 quarters · filed 2022-03-01 | $28.61M derived: sum of 4 quarters · filed 2022-03-01 |
| 2019-12-31 | $86.27M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$30.23M derived: sum of 2 quarters · filed 2022-03-01 | -$32.29M derived: sum of 3 quarters · filed 2022-03-01 | $132.73M 10-K · filed 2022-03-01 |
| 2019-09-30 | -$116.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | -$118.56M derived: sum of 2 quarters · filed 2020-11-06 | $46.46M 10-Q · filed 2020-11-06 | -$117.34M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | -$2.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $162.95M 10-Q · filed 2020-08-06 | -$841.00K derived: sum of 3 quarters · filed 2021-03-01 | $13.82M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $165.01M 10-Q · filed 2020-05-11 | $1.22M derived: sum of 2 quarters · filed 2021-03-01 | $15.88M derived: sum of 3 quarters · filed 2021-03-01 | $80.91M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | -$163.79M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | -$149.13M derived: sum of 2 quarters · filed 2021-03-01 | -$84.10M derived: sum of 3 quarters · filed 2021-03-01 | -$89.08M 10-K · filed 2021-03-01 |
| 2018-09-30 | $14.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $79.69M derived: sum of 2 quarters · filed 2019-11-07 | $74.71M 10-Q · filed 2019-11-07 | $87.92M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | $65.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-05 | $60.05M 10-Q · filed 2019-08-05 | $73.26M derived: sum of 3 quarters · filed 2020-03-02 | $52.86M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | -$4.98M 10-Q · filed 2019-05-09 | $8.23M derived: sum of 2 quarters · filed 2020-03-02 | -$12.17M derived: sum of 3 quarters · filed 2020-03-02 | |
| 2017-12-31 | $13.21M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | -$7.19M derived: sum of 2 quarters · filed 2020-03-02 | -$35.26M 10-K · filed 2020-03-02 | |
| 2017-09-30 | -$20.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | -$48.47M 10-Q · filed 2018-11-07 | ||
| 2017-06-30 | -$28.07M 10-Q · filed 2018-08-09 | |||
| 2016-12-31 | $122.48M 10-K · filed 2019-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |